Cite
Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study
MLA
Andrei R. Shustov, et al. “Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.” Blood, vol. 116, Nov. 2010, p. 2800. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b59fd3cc80a4dc9e8f7693d315a3ecab&authtype=sso&custid=ns315887.
APA
Andrei R. Shustov, Mary Jo Lechowicz, Steven M. Fruchtman, David C. Fisher, Francine M. Foss, Tony Koutsoukos, Youn H. Kim, Nancy L. Bartlett, Madeleine Duvic, Steven M. Horwitz, Jasmine Zain, Patricia L. Myskowski, Maria Delioukina, & Owen A. O’Connor. (2010). Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. Blood, 116, 2800.
Chicago
Andrei R. Shustov, Mary Jo Lechowicz, Steven M. Fruchtman, David C. Fisher, Francine M. Foss, Tony Koutsoukos, Youn H. Kim, et al. 2010. “Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.” Blood 116 (November): 2800. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b59fd3cc80a4dc9e8f7693d315a3ecab&authtype=sso&custid=ns315887.